Does AGE–RAGE Stress Play a Role in the Development of Coronary Artery Disease in Obesity?
Authors:
- 12 February 2022
- journal article
- review article
- Published by Georg Thieme Verlag KG in International Journal of Angiology
- Vol. 31 (01) , 001-009
Abstract
This article deals with the role of AGE (advanced glycation end products)–RAGE (receptor for AGE) stress (AGE/sRAGE) in the development of coronary artery disease (CAD) in obesity. CAD is due to atherosclerosis in coronary artery. The serum/plasma levels of AGE and sRAGE are reduced, while AGE–RAGE stress and expression of RAGE are elevated in obese individuals. However, the levels of AGE are elevated in obese individuals with more than one metabolic syndrome. The increases in the AGE–RAGE stress would elevate the expression and production of atherogenic factors, including reactive oxygen species, nuclear factor-kappa B, cytokines, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, endothelial leukocyte adhesion molecules, monocyte chemoattractant protein-1, granulocyte-macrophage colony-stimulating factor, and growth factors. Low levels of sRAGE would also increase the atherogenic factors. The increases in the AGE–RAGE stress and decreases in the levels of sRAGE would induce development of atherosclerosis, leading to CAD. The therapeutic regimen for AGE–RAGE stress–induced CAD in obesity would include lowering of AGE intake, prevention of AGE formation, degradation of AGE in vivo, suppression of RAGE expression, blockade of AGE–RAGE interaction, downregulation of sRAGE expression, and use of antioxidants. In conclusion, the data suggest that AGE–RAGE stress is involved in the development of CAD in obesity, and the therapeutic interventions to reduce AGE–RAGE would be helpful in preventing, regressing, and slowing the progression of CAD in obesity.Keywords
This publication has 107 references indexed in Scilit:
- Serum Levels of Receptors for Advanced Glycation End Products in Normal-Weight and Obese Children Born Small and Large for Gestational AgeDiabetes Care, 2012
- Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patientsLipids in Health and Disease, 2011
- Fat Mass Is Inversely Associated with Serum Carboxymethyl-Lysine, An Advanced Glycation End Product, in Adults,The Journal of Nutrition, 2011
- Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetesClinical Science, 2010
- Receptor for Advanced Glycation end Products: Its Role in Alzheimer‘s Disease and other Neurological DiseasesFuture Neurology, 2009
- Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general populationNutrition, Metabolism and Cardiovascular Diseases, 2009
- Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by MetalloproteinasesJournal of Biological Chemistry, 2008
- Obesity prevalence from a European perspective: a systematic reviewBMC Public Health, 2008
- Scavenger receptors for oxidized and glycated proteinsAmino Acids, 2003
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988